Traversa Therapeutics has appointed Bharat Chowrira to its board of directors.
Chowrira is currently COO and senior vice president of biopharmaceutical firm Nektar Therapeutics. Before this, he was executive director of worldwide licensing and external research at Merck.
Chowrira joined Merck after its acquisition of RNAi drug shop Sirna Therapeutics, where he served as vice president.
He holds a PhD in microbiology and molecular genetics from the University of Vermont and a JD from the College of Law at the University of Denver.